tbuckley/cabot-search huggingface dataset:
TCT-87 Transcatheter treatment of severe tricuspid regurgitation using the MitraClip® system: 30-day clinical results in 13 consecutive patients.
Authors: Jörg Hausleiter, Daniel Braun, Mathias Orban, Martin Orban, Julinda Mehilli, Andrea Englmaier, Gustavo Lima da Silva, Teppei Murata, Steffen Massberg, Michael Nabauer
Journal: Journal of the American College of Cardiology (2016)
Longitudinal investigation of nasopharyngeal methicillin-resistant Staphylococcus aureus colonization in early infancy: The PATCH birth cohort study
Authors: M.-H. Tsai, C.-Y. Chiu, H.-J. Shih, S.-L. Liao, M.-C. Hua, S.-H. Huang, T.-C. Yao, S.-H. Lai, T.-S. Huang, K.-W. Yeh, L.-C. Chen, K.-W. Su, W.-H. Lim, Y.-J. Chang, C.-H. Chiang, S.-Y. Huang, J.-L. Huang
Journal: Clinical Microbiology and Infection (2016)

The study aimed to determine the long-term Staphylococcus aureus colonization patterns and strain relatedness, and the association between maternal and infant colonization in infancy.A birth cohort study was conducted from January 2012 to November 2014. Nasopharyngeal swabs for S. aureus detection were collected from infants at the age of 1, 2, 4, 6 and 12 months and from mothers when their children were 1-month-old.In total, 254 samples were collected at each planned visit during the first 12-month study. The prevalence of S. aureus colonization decreased in the first year of life, ranging from 61.0% (155/254) at the age of 1 month to 12.2% (31/254) at 12 months. Persistent colonization, defined as a positive culture on four or five occasions, was detected in only 13.8% (35/254) of carriers. Most of the persistent carriers were colonized with methicillin-resistant S. aureus (MRSA) only, and among persistent MRSA carriers, 61.1% (11/18) had indistinguishable genotypes. Of the mothers with MRSA colonization, 77.1% (27/35) had infants who were concomitantly colonized at the age of 1 month; 70.4% (19/27) of the infant-mother paired isolates belonged to indistinguishable or related subtypes, which suggests that surrounding carriers, probably their mothers, may be the possible source for MRSA acquisition in early infancy.Staphylococcus aureus colonization including MRSA was commonly observed in our cohort. Strains of persistent MRSA among infant-mother pairs were usually of indistinguishable genotypes. Therefore, horizontal spread within households is possibly an important factor related to infant MRSA colonization.
Oral Administration of the Opium Alkaloid Noscapine (NOS) Exhibits Potent Anti-Tumor Activity Against Non-Hodgkin’s Lymphomas and Myeloma Cell Lines In Vitro and In Vivo in SCID-beige Murine Xenograft Models.
Authors: Owen O’Connor, J. Mastrella, E. Smith, L. Toner, A. Auerbach, J. P. Leonard
Journal: Blood (2005)
TCT-750 Bivalirudin versus Heparin Anticoagulation in Transcatheter Aortic Valve Interventions. A Systematic review and a Meta-analysis
Authors: Rasha Al-Bawardy, Maday Gonzalez, Jerson Munoz Mendoza, Miguel Alvarez, Daniel Pu, Aman Shah, Arrash Fard, Divyanshu Mohananey, Harish Ramakrishna, Pedro Villablanca
Journal: Journal of the American College of Cardiology (2016)
Phase II study of pegylated liposomal doxorubicin plus vinorelbine in metastatic breast cancer
Authors: S. Del Prete, L. Montella, V. Faiola, R. Guarrasi, G. Busto, R. Addeo
Journal: Journal of Clinical Oncology (2006)

10718 Background: Pegylated liposomal doxorubicin and vinorelbine are active single agents in metastatic breast cancer (MBC) and lack overlapping toxicity. The possibility of combining these two drugs therefore seems attractive. Methods: Twenty-five patients with MBC entered a phase II study of pegylated liposomal doxorubicin 40 mg/m 2 intravenously (i.v.) on day 1 plus vinorelbine 25 mg/m 2 i.v. on day 1 and vinorelbine 60 mg/m 2 oral on day 14, every 4 weeks. A two-staged Simon accrual design was adopted for this phase II trial. Patients were required to have measurable disease, previous chemotherapy with or without an anthracycline-containing regimen, and a normal left ventricular ejection fraction (LVEF). Results: Twenty-one patients with MBC were eligible, assessable for response and toxicity. The overall response rate (on an intent-to-treat basis) was 36% (9 of 25; 95% CI, 20%-54%). One complete response and 8 partial responses were noted. In addition, 11 patients (44%) had stable disease of &gt; 4 months duration, and 5 patients (20 %) had disease progression. Median time to disease progression was 10 months (range, 3–38 months) and median overall survival was 15 months (range, 4 to &gt; 62 months). Neutropenia was the most frequent toxicity (grade 4 in 30% of patients and 19% of cycles), but neutropenic fever was seen in only 3 cases. No septic deaths occurred. Nonhematologic grade 3 side effects included skin toxicity (palmar-plantar erythrodysesthesia syndrome, 8%) and mucositis (14%). Late alopecia was seen in 51% of patients (grade 1 in 39%, and grade 2 in 12%). The median LVEFs were 64% (range, 50%-81%) at baseline and 62% (range, 37%-70%) after treatment. Only one patient presented an LVEF decrease to &lt; 50%; however, no clinical heart failure was noted, and this patient recovered normal values after cessation of therapy. Conclusions: The combination of pegylated liposomal doxorubicin and vinorelbine can be safely administered to patients with anthracycline-pretreated MBC and is active in this population. Final data analysis will be presented. No significant financial relationships to disclose.
TCT-542 Usefulness of QFR measurement for non-culprit lesion of ACS patients
Authors: Takeyoshi Kameyama, Takashi Kubo, Hiroki Emori, Yasushi Ino, Yoshiki Matsuo, Takashi Yamano, Hiroshi Aoki, Tsuyoshi Nishiguchi, Yuichi Ozaki, Makoto Orii, Akio Kuroi, Takashi Tanimoto, Tomoyuki Yamaguchi, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2016)
TCT-161 5 years follow-up of biolimus eluting stents versus everolimus eluting in ST-segment elevation myocardial infarction presenting patients: Results from Compare II trial
Authors: George Vlachojannis, Valeria Paradies, Sjoerd H. Hofma, Mario Togni, Nicolas Vazquez, Mariano Valdes, Vassilis Voudris, ton slagboom, Jean-Jacques Goy, Andre Vuilliomenet, Antonio Serra, Ramiro Trillo, Peter Den Heijer, Martin van der Ent, Pieter Smits
Journal: Journal of the American College of Cardiology (2016)
Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program
Authors: M. Di Maio, C. Gallo, S. Barbera, A. Ceribelli, T. Gamucci, L. Isa, E. Piazza, N. Borsellino, V. Zagonel, C. Gridelli
Journal: Journal of Clinical Oncology (2006)

7089 Background: Trials testing chemotherapy for elderly pts with SCLC are scanty. Gemcitabine (Gem) is active and well tolerated. The G-STEP program looked for optimal 2-drug combination of G with either vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Methods: Extended stage SCLC pts, aged &gt;70 years, PS 0–2, were eligible. Dose of G was 1,000 mg/m 2 , dd 1&amp;8, every 3 weeks in all the four combinations. As safety data in the elderly were already available for Gem+Vin (Vin dose 25 mg/m 2 , dd 1&amp;8), a two-stage minimax flexible design was applied with response as end-point: ≥13 responses/30 pts required at 1 st stage, with p 0 =0.40, p 1 =0.60, α and β=0.10. For Gem+Car, Gem+Cis, Gem+Eto a phase 1–2 Bayesian design to select optimal dose was applied (Thall &amp; Russell, Biometrics, 1998), with 3 possible outcomes for each patient: “active” (response and no unacceptable toxicity [UT]), “inactive” (no response, no UT), or “toxic” (UT independently of response). A response rate [RR] ≥60% and a rate of UT ≤25% were acceptable. Dose levels to explore were: Car: AUC 3.5 / 4 / 4.5, d1; Cis: 50 / 60 / 70 mg/m 2 , d1; Eto: 60 / 70 / 80 mg/m 2 , dd 1,2,3. Results: From May 2000 to September 2005, 78 eligible pts were enrolled; median age was 74 years (42% of pts older than 75yrs). In the whole group, median progression-free survival and overall survival were 20.3 weeks (95% CI 17.6 - 24.1) and 33.7 weeks (95% CI 23.7 - 41.6), respectively. Study of Gem+Vin was closed for inactivity after 1st stage with 11 responses / 30 pts (RR 36.7%, 95% exact CI: 19.9–56.1). Gem+Eto arm was closed after 10 pts (5 inactive and 5 toxic) because too high probability (0.994) of inactivity. Gem+Cis arm was closed after 12 pts (2 active, 5 inactive, 5 toxic) because too high probability (0.988) of inactivity. With Gem+Car (December 2005: 2 pts ongoing, 24 analysed: 12 active, 6, inactive and 6 toxic), RR in the 20 pts receiving Car at AUC 3.5 was 60% (95% exact CI: 36.1–80.9). Conclusions: The combination of gemcitabine and carboplatin seems promising for future trials in elderly patients with extended SCLC. The G-STEP program was supported by GIOGER. No significant financial relationships to disclose.
TCT-633 Treatment of mitral regurgitation in patients with severely impaired left ventricular ejection fraction with the MitraClip system – MVARC outcome
Authors: Christian Frerker, Tobias Schmidt, Michael Schlueter, Felix Kreidel, Hannes Alessandrini, Thomas Thielsen, Dimitry Schewel, Jury Schewel, Ulrich Schaefer, Karl-Heinz Kuck
Journal: Journal of the American College of Cardiology (2016)
TCT-396 Performance of drug-coated balloons on in-stent restenosis after two-stent implantation for left main coronary artery bifurcation lesions
Authors: Akimune Kuwayama, Kazushige Kadota, katsuya miura, Masanobu Ohya, Takenobu Shimada, Hidewo Amano, Shunsuke Kubo, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
Journal: Journal of the American College of Cardiology (2016)
Loss of TM-Dependent PC-Activation Predisposes to Diabetic Nephropathy: Potential Role of Endothelial Apoptosis.
Authors: Berend Isermann, Madhusudhan Thati, Ilya Vinnikov, Stefanie Herzog, Sina Huntscha, Robert Bünder, Hartmut Weiler, Angelika Bierhaus, Peter P. Nawroth
Journal: Blood (2005)
New criteria for complete response (CR) after definitive chemoradiotherapy for recectable squamous cell carcinoma of esophagus
Authors: A. Takeda, I. Koyama, Y. Otani, Y. Sasaki, T. Dikiya
Journal: Journal of Clinical Oncology (2006)

14032 Background: According to a series of clinical trials, definitive chemoradiotherapy for esophageal cancer has become one of the accepted treatment methods even for respectable-stage disease. But preciously outlined CR criteria after definitive chemoradiotherapy has not been established. The purpose of this study is to assess the validity of new criteria for CR of esophageal cancer treated with definitive chemoradiotherapy. Methods: We reviewed 40 patients with T1b-T4, N0–1, M0 (clinical TNM stageI-III) resectable esophageal cancer treated with definitive chemoradiotherapy from April 2000. The patients received 5-Fluorouracil combined with cisplatin plus 50.4–60gy of radiation. We have here designated the CR criteria after definitive chemoradiotherapy 1)able to observe the entire esophagus by endoscopy with disappearance of the tumor lesion and ulceration 2)absence of cancer cells in pathological evaluation 3) no appearance of distant metastasis by CT scan during a series of treatment, in addition 4) no new recurrent lesions at least 6 months using the multimodality observation from determination of primary-CR. Results: Primary CR was achieved in 26 in 40 patients (65%) at the end of a series of treatment. Primary-CR rate in patients with stageI,II,III was 100% (3 out of 3), 85.7% (18 out of 21), 31.2% (5 out of 16) with a remarkable difference between TNM StageI,IIand III patients. There were 6 patients (33.3%) who were confirmed to have local recurrence in stageII esophageal cancer after determination of primary-CR. Likewise, one patient (20%) of recurrent disease in stageIII. Time at first relapse from the initial date of treatment to determine CR was 50–152 days in all recurrent patients. There were no patients with recurrence in the patients who could maintain CR for 6 months over after the determination of CR with a median follow-up of 13 months. Patients maintaining CR after the determination of CR have a significant good survival rate compared with recurrent patients after determination of CR (P&lt;0.001) Conclusions: Our new criteria considered the time from determination of CR appear to be useful for clinical application, predict favorable survival for respectable esophageal cancer patients treated with definitive chemoradiotherapy. No significant financial relationships to disclose.
P0488 : Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection
Authors: X. Zhou, L. Xu, W. Wang, H. Blokzijl, Y. Wang, D. Sprengers, H.L.A. Janssen, P.E. de Ruiter, L.J. van der Laan, J. Neyts, H.J. Metselaar, N. Kamar, M.P. Peppelenbosch, Q. Pan
Journal: Journal of Hepatology (2015)
When radiology meets gastroenterology: an unusual impact
Authors: Grigoriy E Gurvits
Journal: Gut (2016)

A 37-year-old male with small intestinal Crohn's disease requiring distant previous ileal resection and currently in clinical remission without medical therapy was admitted to the hospital with several weeks of migrating abdominal pains that were progressively localised to the right lower quadrant and now associated with vomiting. His abdomen was distended and tender to palpation without guarding or rebound. Laboratory analysis showed haemoglobin level of 16.7 g/dL, white blood cell count of 11 800/mL, creatine level …
Respective IL-17A production by γδ T and Th17 cells and its implication in host defense against chlamydial lung infection
Authors: Hong Bai, Xiaoling Gao, Lei Zhao, Ying Peng, Jie Yang, Sai Qiao, Huili Zhao, Shuhe Wang, YiJun Fan, Antony George Joyee, Zhi Yao, Xi Yang
Journal: Cellular and Molecular Immunology (2016)
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration
Authors: Glenn J. Jaffe, Thomas A. Ciulla, Antonio P. Ciardella, Francois Devin, Pravin U. Dugel, Chiara M. Eandi, Harvey Masonson, Jordi Monés, Joel A. Pearlman, Maddalena Quaranta-El Maftouhi, Federico Ricci, Keith Westby, Samir C. Patel
Journal: Ophthalmology (2016)
Treatment Side Effects
Authors: Nauman Moazzam, Ashar A. Malik, Syed A. Mehdi, Anil Potti
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.13.3032 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12089235 Treatment Side Effects Case 3. Fluorouracil-Induced Exacerbation of Systemic Lupus Erythematosus Nauman MoazzamxNauman MoazzamSearch for articles by this author , Ashar A. MalikxAshar A. MalikSearch for articles by this author , Syed A. MehdixSyed A. MehdiSearch for articles by this author , Anil PottixAnil PottiSearch for articles by this author Show More University of North Dakota School of Medicine and Health Sciences, Fargo, ND https://doi.org/10.1200/JCO.2002.20.13.3032 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Prognostic impact of response to second-line chemotherapy on overall survival of patients with advanced gastric cancer
Authors: S. Kim, M. Hwang, Y. Park, S. Park, Y. Kim, K. Ryu, J. Lee, Y. Park, N. Kim, S. Park
Journal: Journal of Clinical Oncology (2009)

e15551 Background: It has been debated on whether tumor response to first-line chemotherapy (CT) would be reliable predictor for overall survival (OS) of cancer patients (pts). In case of advanced gastric cancer (AGC), many pts receive 2 nd line CT after failure to 1 st line treatment, so response to 2 nd line CT as well as 1 st line could affect OS. Methods: We retrieved clinical data of a total of 1,335 pts with AGC treated with palliative CT from January 2000 to December 2006 in National Cancer Center, Korea, including 757 pts who also received 2 nd line CT. Responses to 1 st and 2 nd line CT were evaluable in 504 pts. Retrospective analysis was done to find correlation between objective tumor response to 1 st and 2 nd line CT and OS of the 504 pts, whom we divided into 4 groups: responders to both 1 st and 2 nd line CT (RR group); responders to 1 st but not to 2nd line CT (RN group); responders to 2 nd but not to 1 st line CT (NR group); and nonresponders to both 1 st and 2 nd line CT (NN group). Results: Objective response rate of 1 st and 2 nd line CT was 41.7% and 12.3%, respectively. Responders to 1 st line CT had a trend to respond to 2 nd line CT (ORR of 2 nd line CT in responders vs nonresponders to 1 st line CT: 15.7% vs 9.9%, p = 0.049). 33/177/29/265 pts were assigned to each of RR/RN/NR/NN group, respectively. With median follow-up of 48.7 mo (range 23.2 - 93.7), median OS was 12.7 mo (95% CI 11.8–13.6). Baseline characteristics were balanced between 4 groups except higher hemoglobin and serum albumin level in RR group, younger median age in NN group, and fewer pts with poor performance status or poorly differentiated histology in NR group. Overall survival of RR, RN, NR, and NN group was 31.8 mo, 15.5 mo, 18.9 mo, and 9.2 mo, respectively (p&lt;0.001). Multivariate analysis revealed relapsed disease after curative surgery, well-differentiated histology, absence of pulmonary metastasis, higher serum albumin level, lower serum bilirubin and alkaline phosphatase level, response to both of 1 st line and 2 nd line CT were reliable factors for favorable survival. Conclusions: Among the patients who received 2 nd line chemotherapy for AGC, response to 2 nd line CT was strongly associated with OS regardless of previous response to 1 st line CT. No significant financial relationships to disclose.
P0436 : Pentraxin-3 induces hepatic stellate cell activation and attenuates the inflammatory response during hepatic injury
Authors: L. Perea, M. Coll, A. El Taghdouini, D. Rodrigo-Torres, D. Blaya, O. Morales-Ibanez, M. Llopis, L. Van Grunsven, J. Caballeria, P. Ginès, P. Sancho-Bru
Journal: Journal of Hepatology (2015)
Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study
Authors: Hui-Yao Huang, Ju-Fang Shi, Lan-Wei Guo, Xin-Yu Zhu, Le Wang, Xian-Zhen Liao, Guo-Xiang Liu, Ya-Na Bai, A-Yan Mao, Jian-Song Ren, Xiao-Jie Sun, Kai Zhang, Jie He, Min Dai
Journal: The Lancet (2016)
Production of BMP4 By Endothelial Cells Is Crucial for Endogenous Thymic Regeneration
Authors: Tobias Wertheimer, Enrico Velardi, Christian Brede, Shiyun Xiao, Christopher C Kloss, Andreas Beilhack, Nancy Manley, Jason M. Butler, Shahin Rafii, Marcel van den Brink, Jarrod A Dudakov
Journal: Blood (2015)
EL ANALISIS MUTACIONAL DE GNAS EN MUESTRA LIQUIDA DE PANCREAS POR USE-PAAF MEJORA EL DIAGNOSTICO DE NEOPLASIA MUCINOSA PAPILAR INTRADUCTAL (NMPI) Y PANCREATITIS CRONICA (PC)
Authors: C Montironi, C Sánchez-Montes, EC Vaquero, E Samper, J Muñoz, S Castellví, M Cuatrecasas, O Sendino, G Fernández-Esparrach, À Ginès
Journal: Endoscopy (2016)

Introducción: PC y NMPI ocasionan cambios morfológicos similares en el páncreas (quistes, dilatación ductal) que dificultan el diagnóstico diferencial. Además, PC y NMPI pueden coexistir. Las mutaciones en KRAS son prevalentes en la NMPI pero poco específicas. Las mutaciones en GNAS son específicas de lesiones mucinosas y útiles para tipificar de lesiones quísticas pancreáticas. Se desconoce la utilidad de las mutaciones de GNAS en el diagnóstico de la PC.
TCT-283 Impact of Successful Percutaneous Coronary Intervention on Chronic Total Occlusion Outcomes in Patients with Well-developed Coronary Collateral Flow.
Authors: Seung-Woon Rha, Se Yeon Choi, Byoung Geol Choi, Jae Kyeong Byun, Jun Hyuk Kang, Woo Hyeun Kim, Ja Yeon Choi, James Hall, Sung Hun Park, SunKi Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
Circulating tumor cell detection: A direct comparison between the CellSearch System, the AdnaTest, and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer
Authors: L. Y. Dirix, H. Elst, I. Benoy, I. Van der Auwera, A. Prové, H. Wuyts, H. Maes, P. van Dam, P. Huget, P. Vermeulen
Journal: Journal of Clinical Oncology (2009)

e22117 Background: The detection, enumeration and isolation of circulating tumor cells (CTC) has considerable potential to influence the clinical management of patients with breast cancer. There is however a substantial variability in the rates of positive samples using existing detection techniques. Methods: This study was designed to compare three techniques for detecting CTC in blood of 80 patients with metastatic breast cancer (MBC) and 20 healthy controls: the CellSearch System, which is an automated, standardized and regulatory-approved system for the immunocytochemical detection and quantification of CTC in blood; ii) the AdnaTest Breast Cancer Select/Detect, which involves the detection of tumor-associated transcripts by RT-PCR after an immunomagnetically enrichment of tumor cells; iii) an in-house developed multimarker qRT-PCR assay, which involves the quantification of tumor-associated transcripts (CK-19 and MAM) by qRT- PCR. Results: As a result, 23% of patients with MBC were positive by the CellSearch System (≥5 CTC), 22% by the AdnaTest (&gt;0.30 ng/μl for any of the amplicons), 31% by qRT-PCR for CK-19 and 49% by qRT-PCR for MAM. Samples were more likely to be positive by qRT-PCR for at least one mRNA marker than by the CellSearch System (P&lt;0.001) or the AdnaTest (P &lt;0.001). The concordance between samples analyzed by the CellSearch System and the AdnaTest was substantial (κ = 0.667, P &lt;0.001). Agreement between both detection techniques was observed in 88% of blood samples. When the CellSearch System was compared with the qRT-PCR assays for CK-19 and MAM, we observed agreement percentages of 78% and 58%, respectively (κ = 0.462, P &lt;0.001 and κ = 0.159, P = 0.09). Agreement between the AdnaTest and the qRT-PCR assays for CK-19 and MAM was observed in 78% and 53% of blood samples, respectively (κ = 0.443, P &lt;0.001 and κ = 0.05, P = 0.607). Conclusions: We observed a substantial variation in the detection rates of CTC in blood from MBC patients using three different techniques. A higher rate of positive samples was observed using a combined qRT-PCR approach for CK-19 and MAM, which suggests that this is currently the most sensitive technique for detecting CTC. No significant financial relationships to disclose.
TCT-112 Pretreatment with P2Y12 receptor antagonists is not associated with improved patency of infarct related-artery in NSTEMI – A report from SCAAR
Authors: Christian Dworeck, Inger Haraldsson, Oscar Angeras, Jacob Odenstedt, Dan Ioanes, Petur Petursson, Sebastian Volz, Per Albertsson, Jonas Persson, Sasha Koul, David Erlinge, Truls Råmunddal, Elmir Omerovic
Journal: Journal of the American College of Cardiology (2016)
Whole-Exome Resequencing Identifies Somatic Mutations Of BCOR and BCORL1 Transcriptional Corepressor Genes and Major Cohesin Complex Component Genes In Pediatric Acute Myeloid Leukemia
Authors: Norio Shiba, Kenichi Yoshida, Yasunobu Nagata, Ayana Kon, Yusuke Okuno, Yuichi Shiraishi, Motohiro Kato, Myoung-ja Park, Kentaro Ohki, Junko Takita, Takashi Kanazawa, Kazuko Kudo, Etsuro Ito, Masashi Sanada, Daisuke Tomizawa, Akio Tawa, Souichi Adachi, Satoru Miyano, Seishi Ogawa, Yasuhide Hayashi
Journal: Blood (2013)
TCT-8 Impact of Aspirin Resistance on Outcomes after Coronary Events
Authors: Christine Chung, Ajay Kirtane, Claire Litherland, Bernhard Witzenbichler, Giora Weisz, Thomas Stuckey, Bruce Brodie, Michael Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy Henry, David Cox, Peter L. Duffy, Ernest Mazzaferri, Roxana Mehran, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)